BiomX Inc. HLSQ

Company Overview

BiomX Inc. is a clinical-stage biotechnology company focused on developing therapies based on naturally occurring and engineered bacteriophages, commonly referred to as phages. The company operates within the biotechnology, precision medicine, and infectious disease sectors, with a primary emphasis on treatments targeting chronic bacterial infections and microbiome-related conditions. BiomX’s core business model centers on discovering, engineering, and developing phage-based therapeutics designed to selectively target pathogenic bacteria while preserving beneficial microbiota. Its principal revenue and value drivers are tied to clinical development programs, intellectual property related to phage engineering, strategic collaborations, and research partnerships.

The company’s lead programs have focused on serious infections associated with cystic fibrosis and diabetic foot osteomyelitis, particularly infections caused by Pseudomonas aeruginosa and Staphylococcus aureus. BiomX positions itself as a precision-phage therapeutics company through its proprietary discovery and engineering platform, which integrates computational biology, microbiome analytics, and synthetic biology capabilities. BiomX was founded in Israel in 2015 based on research originating from the Weizmann Institute of Science and was later combined with Chardan Healthcare Acquisition Corp. through a public market transaction, resulting in its Nasdaq listing under the ticker PHGE.